It can lead to increased appetite, hormonal imbalances, and decreased metabolism, making it more difficult to lose weight and maintain overall health

event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase

Description: GHK-Cu, also known as Copper Tri-Peptide, is a scientific innovation in skincare, offering remarkable rejuvenating properties
For this clinical trial, we aim to recruit 30 adult patients, aged 20 years and older, who have been diagnosed with CRSwNP based on established diagnostic criteria, including persistent nasal congestion, rhinorrhea, and nasal obstruction lasting over 12 weeks, along with evidence of nasal polyps confirmed through endoscopy or imaging [13]
Boost your Mood B-12 deficiency can lead to anxiety, depression, and mood swings
Neuere Studien erweitern das Forschungsspektrum von GHK-Cu ueber Haut und Haare hinaus